Atomwise Stock
Atomwise develops artificial intelligence systems using powerful deep learning algorithms and supercomputers for drug discovery.
Sign up today and learn more about Atomwise Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Atomwise Stock
The Atomwise Advantage Using computers to discover medicines is a great idea, but execution is everything. With lives and budgets on the line, accuracy matters. Previous attempts haven't always met expectations. The techniques of the day were limited by the knowledge and computers available. Today, things are different. They have invented cutting-edge machine learning algorithms that are built specifically for the world's most powerful computers. They use one of the world's top supercomputers to analyze databases 1000 times larger than those used in the past. This lets us deliver what many others can't: precise and reliable medicinal predictions.
Funding History
| January 2013 | $225K |
|---|---|
| December 2014 | $120K |
| March 2015 | $225K |
| June 2015 | $6.0M |
Management
CEO
Abraham Heifets
CTO
Dr. Izhar Wallach
COO
Alexander Levy
Press
TechCrunch - Aug, 11 2020
Atomwise’s machine learning-based drug discovery service raises $123 millionForbes - Oct, 26 2019
How Neural Nets Will Personalize Medicine: Meet The Startup That’s Changing How We Find New DrugsTechCrunch - May, 3 2016
Tall poppy syndrome and the Canadian opportunityTechCrunch - Jan, 10 2016
Investing In Artificial IntelligenceTechCrunch - Mar, 25 2015
The Top 10 Startups Of Y Combinator Winter ’15 Demo Day 2TechCrunch - Mar, 25 2015
47 Startups That Launched At Y Combinator Winter 2015 Demo Day 2TechCrunch - Mar, 24 2015
YC-Backed Notable Labs Provides Personalized Medical Testing For Brain Cancer PatientsTechCrunch - Mar, 6 2015
YC-Backed Atomwise Discovers Drugs For Diseases That Don’t Even Exist YetEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
